U 86983

structure given in first source

Also Known As:

2-(4-morpholinyl)-8-(3-pyridinylmethoxy)-4H-1-benzopyran-4-one; U-86983

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Neointima 10/01/1994 - "Continual (2-week) i.v. administration of U-86983 (216 mg kg-1 day-1) resulted in a mean plasma drug concentration of 2.39 micrograms/ml (blood level, approximately 3.5 microM) and a 42% (P = .003) reduction in the neointima/media ratio of the injured artery. "